Somatostatin fibers and their relationship to specific cell types (GH and TSH) in the rat anterior pituitary

Fibers immunocytochemically stained for somatostatin (growth hormone-release-inhibiting hormone) were localized in the anterior pituitaries of rats. Initial studies of fiber localization involved the use of thick frozen (30 micron) sections which allowed visualization of fibers as they coursed along the periphery of the anterior lobe in the sagittal plane and along blood vessels throughout the lobe. Fibers were observed most often at the rostral, caudal, and lateral poles. In thinner (1-3 micron) paraffin sections, stained somatostatin fibers could be localized in close proximity to cells that were stained for growth hormone or thyroid stimulating hormone in a double stain with a second peroxidase substrate. These and our previous light microscopic studies show that a few neuronal processes containing neurotransmitters extent beyond the level of the median eminence (or perhaps from a peripheral source), penetrate the anterior lobe in specific regions, and lie in close proximity to cells known to be controlled by the transmitter.     

Levothyroxine Dosing in Older Adults: Recommendations Derived From The Baltimore Longitudinal Study of Aging

ObjectiveAs thyroid hormone metabolism slows with advancing age, treatment dosing requirements change. Guidelines recommend titration from a low starting dose for older adults with hypothyroidism while providing weight-based estimates for younger populations. However, rapid replacement may be appropriate with acute onset of overt hypothyroidism. Therefore, a weight-based recommendation specific to older adults is needed.MethodsWe determined mean levothyroxine dose using actual and ideal body weight (IBW) ratios for the outcome of euthyroid on therapy relative to assay-specific and proposed age-specific ranges for independently living participants aged ≥65 years in the Baltimore Longitudinal Study of Aging. We examined risk factors to identify those at highest risk of overtreatment using regression analyses adjusted for potential covariables and clustering to account for multiple visits per individual.ResultsOne hundred eighty-five participants aged ≥65 years were on levothyroxine at 645 eligible visits. At euthyroid visits, participants were on an average dose of 1.09 μg/kg (1.35 μg/kg IBW), with 84% of euthyroid individuals on a dose of <1.6 μg/kg. Average euthyroid dose did not differ by sex using either actual body weight (ABW) or IBW. For obese individuals, mean euthyroid dose was lower if calculated using ABW (0.9 μg/kg vs 1.14 μg/kg; P < .01) but similar if calculated using IBW (1.42 vs 1.32 μg/kg IBW; P = .41) compared with those with a body mass index of <30.ConclusionThyroid hormone dose per body weight estimates for replacement in older adults (1.09 μg/kg ABW or 1.35 μg/kg IBW) are one-third lower than current weight-based dose recommendations for younger populations.     

Behavioral effects of thyrotropin releasing hormone in frontal decorticated rats

A low dose intracerebroventricular injection of thyrotropin releasing hormone (TRH, 100 ng) changed many behavioral responses in the rat. TRH increased locomotion, scratching, body shaking, piloerection, and rearing, but decreased sniffing, and resting. Ablation of frontal neocortex further enhanced the TRH effects on locomotion and resting. A dose effect of TRH (0, 5, 10, 50, 100 ng) to increase general activity was established and the effect was further enhanced by decortication. In our test situations decortication had no effect by itself. Since the TRH effects became much more pronounced without the frontal neocortex it appears that the cortex exerts a powerful inhibitory effect to moderate the TRH effects. The TRH effect does not depend upon the frontal cortex, actually a cortical function is to dampen the TRH effects on various behavioral responses.     

Effects of thyrotropin on thyroid chromatin: Enhanced sensitivity to micrococcal nuclease and increased nuclear protein phosphorylation

Thyroid slices were incubated with or without TSH for 2 or 5 h. Nuclei were then prepared, subjected to mild digestion with micrococcal nuclease, and centrifuged at 1200 × g. The amount of DNA in 1200 × g supernatants was increased by TSH at 5 h, but not at 2 h. In parallel studies, thyroid slices were incubated with ³²P_i and labeling of acid-soluble nuclear proteins was examined. TSH-dependent increases in labeling of histones H1 and H3, and of the high mobility group protein HMG 14, were observed at 2 h; however, there were no apparent changes in TSH-dependent labeling between 2 and 5 h, in nuclease-sensitive or in bulk chromatin. These results suggest that the observed TSH-dependent changes in the micrococcal nuclease-sensitivity of thyroid nuclear chromatin were not induced directly by changes in the phosphorylation of the histones or HMG 14.     

Chronic dihydroergotoxine administration sets on receptors for enkephalin and thyrotropin releasing hormone in the aged-rat brain

Dihydroergotoxine (DHET) is comprised of equal part of the mesylates of dihydroergocristine, dihydroergocornine and dihydroergocryptine. In the standard radioreceptor assays, DHET components displaced the CNS-receptor binding of [3H]-enkephalin (ENK) and [3H]thyrotropin releasing hormone (TRH). The inhibitory effect of DHET on ENK binding was competitive, and an allosteric effect seems to be involved in the DHET inhibition of TRH binding to its receptor. Intraperitoneal injections of DHET (1 mg/kg/day) to aged rats for 14 days resulted in a significant increase of ENK and TRH binding in the cerebral cortex. Scatchard plots of saturation experiments indicate that the increase of ENK binding is due to the increased affinity of the binding sites, and the increase of TRH binding reflects an increase in numbers of binding sites. The results suggest that the therapeutic efficacy of DHET is derived initially from its effects on the ENK and TRH receptors especially in the cerebral cortex, which in turn influence the function of monoaminergic neurons.     

Thytropin increases the iodine content of rat circulating thyroglobulin as measured by equilibrium density gradient centrifugation

In previous work we demonstrated that circulating thyroglobulin contains very little or no iodine. We have now characterized circulating thyroglobulin following administration of thyrotropin (TSH) to determine whether its iodine content remains low or increases after stimulation. The iodine content of circulating thyroglobulin was estimated from its density determined by equilibrium density gradient (isopycnic) centrifugation. TSH stimulated thyroglobulin from 182 ± 28 ng/ml to 571 ± 83 ng/ml at 8–14 h. Circulating thyroglobulin in the basal state had a density consistent with very little or no iodine. Its density increased following TSH to a maximum at 8–14 h which was nearly the same as the density of thyroglobulin extracted directly from the thyroid. To determine whether selective peripheral metabolism, based on the degree of iodination, could account for the density shift, purified rat thyroid thyroglobulin was injected into thyroidectomized rats. The density of thyroglobulin remained unchanged for 25 h during which time it was metabolized by more than 97%. Therefore, selective metabolism of thyroglobulin based on iodine content did not occur. We conclude that TSH causes a marked increase in the iodine content of circulating thyroglobulin. It is most likely that in the basal state circulating thyroglobulin comes from selective release of poorly iodinated molecules, while after TSH, it comes from release of previously synthesized, iodinated and stored molecules.